Real World Evidence (RWE) & Randomized Control Trial (RCT) Data on IGlarLixi (Soliqua) versus Premixes

Symposium on “Real World Evidence (RWE) & Randomized Control Trial (RCT) Data on IGlarLixi (Soliqua) versus Premixes” – May 9, 2024

The Department of Endocrinology, in collaboration with the Medical Professional Education Department (MPED) at North West General Hospital & Research Centre (NWGH&RC), organized an insightful symposium on IGlarLixi, a novel combination of insulin glargine U100 and the short-acting GLP-1 receptor agonist lixisenatide.

On May 9, 2024, Dr. Arshad Hussain presented compelling scientific evidence from studies comparing IGlarLixi (Soliqua) to premixed insulin regimens. His discussion emphasized the critical role of Real World Evidence (RWE) and Randomized Control Trials (RCTs) in assessing the efficacy and safety of these treatment options for patients with diabetes.

The symposium attracted a diverse audience, including healthcare professionals, medical students, and researchers. Dr. Hussain highlighted key findings from both RWE and RCTs, providing a balanced perspective on the strengths of each treatment modality. This event underscored MPED’s commitment to delivering high-quality medical education and fostering a deeper understanding of innovative therapies through evidence-based research.